Biomx Inc Total Liabilities
Biomx Inc total liabilities. Based on the latest financial reports, Biomx Inc (PHGE) has total liabilities worth $15.68 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PHGE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biomx Inc (2017–2024)
Total liabilities of Biomx Inc from 2017 to 2024. This chart illustrates how Biomx Inc's total liabilities have evolved over time, based on quarterly financial data. Explore PHGE long-term investments to assets to see how much of total assets are deployed in long-term investments.
Biomx Inc Competitors by Total Liabilities
The table below lists competitors of Biomx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MT Educare Limited
NSE:MTEDUCARE
|
India | Rs2.61 Billion |
|
EKF Diagnostics Holdings Plc
LSE:EKF
|
UK | GBX10.76 Million |
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
India | Rs99.34 Million |
|
Magnetite Mines Ltd
AU:MGT
|
Australia | AU$4.31 Million |
|
MFC Industrial Real Estate Investment Trust
BK:MIT
|
Thailand | ฿139.44 Million |
|
Baroyeca Gold & Silver Inc
V:BGS
|
Canada | CA$304.13K |
|
Usha Martin Education & Solutions Limited
NSE:UMESLTD
|
India | Rs23.70 Million |
|
Fsport AB
ST:FSPORT
|
Sweden | Skr1.12 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Biomx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Biomx Inc asset portfolio.
Liquidity & Leverage Metrics
Biomx Inc Total Liabilities Ratios Explained
Biomx Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomx Inc (2017–2024)
The table below shows the annual total liabilities of Biomx Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $19.09 Million | -13.04% |
| 2023-12-31 | $21.95 Million | -10.39% |
| 2022-12-31 | $24.49 Million | -19.58% |
| 2021-12-31 | $30.45 Million | +136.20% |
| 2020-12-31 | $12.89 Million | +68.22% |
| 2019-12-31 | $7.67 Million | +203.20% |
| 2018-12-31 | $2.53 Million | +2.76% |
| 2017-12-31 | $2.46 Million | -- |
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more